Companies ›Healthcare ›AIDR.CD

AIDR.CD — — Advanced Medical Equipment & Technology

Rocket Doctor AI Inc

$0,59

Open in Charts → Attach watcher ⌖

— —

USD

Set alert

Last 30 days

1D5D1M3M6MYTD1Y5YMax

Live price chart loads from the market-data widget.

Mcap

—

P/E

—

EV / Rev

—

Div yield

—

Op margin

—

ROE

-76,6 %

Net margin

—

Debt / equity

0,46

Beta

—

52w range

—

Volume

—

Day range

—

Prev close

—

Open

—

Next earnings

—

Ex-dividend

—

TR 1Y

—

About

Rocket Doctor AI Inc is a healthcare technology company that provides AI-driven diagnostic and treatment solutions for medical professionals.

Business. Rocket Doctor AI Inc (AIDR.CD) is a healthcare company operating within the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of healthcare equipment. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

ActivityHealthcare Equipment

Generated · model-assisted

Sell-side consensus

BUY1 analysts

1 buy0 hold0 sell

Avg 12m price target2,10

Analyst recommendations

1 analysts · consensus Buy

Buy1

Hold0

Sell0

12-month price target

2,10

Consensus of sell-side coverage.

Upcoming events

— missing data

See all catalysts →

At a glance

Score

—

not yet scored

Valuation

—

valuation pending

Analysts→

Buy

1 analysts · indicative

Ownership

—

not yet wired

Profitability→

-76,6 %

return on equity

Quality

—

not yet scored

What drives this business

The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.

— missing data

News & coverage

No recent newsroom coverage mentioning AIDR.

Sector rotation

Sector1D1Mvs mkt

Materials+2,3 %+6,6 %+1,7 %

Communication Services+2,2 %−5,5 %+1,6 %

Energy+0,6 %+3,3 %+0,0 %

Health Care · THIS SECTOR+0,6 %−0,8 %+0,0 %

Information Technology+0,6 %+6,7 %+0,0 %

Consumer Discretionary+0,4 %+7,6 %−0,2 %

Financials−0,3 %−2,8 %−0,9 %

Consumer Staples−0,4 %+2,5 %−1,0 %

Real Estate−0,7 %+10,9 %−1,3 %

Industrials−1,9 %−3,1 %−2,5 %

Utilities−1,9 %+28,2 %−2,5 %

Developing storylines

No tracked sagas currently linked to AIDR.CD. Browse all sagas →

Analysis

AI analysis

Generated · analysis pipeline · tier hybrid · as of 2026-08-04 ↑ At a glance

Opportunity

— missing data

Upcoming catalysts

Scheduled public events. Informational only — not investment advice.

Macro
Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
Macro & political
ElectionSE Swedish Election2026-09-14 · SE
ElectionUS U.S. Midterms2026-11-03 · US
ElectionFR French Legislative2027-06-01 · FR

Pre-earnings brief

— missing data

Signals & dispatch

peak dispatch · —

Composite-score breakdown

Synthesis

Business

Rocket Doctor AI Inc (AIDR.CD) is a healthcare company operating within the Advanced Medical Equipment & Technology industry. The firm primarily engages in the sale of healthcare equipment. Specific details regarding operating segments, headquarters location, and primary stock exchange listings are not available in the provided data.

Classification92 %

SectorHealthcare

Business sectorHealthcare Services & Equipment

IndustryAdvanced Medical Equipment & Technology

ActivityHealthcare Equipment

AI synthesis

GENERATED

Rocket Doctor AI Inc has a current ratio of 1.8, indicating moderate liquidity, but its operating cash flow of -841,000 CAD suggests ongoing cash outflows from operations. The company's debt-to-equity ratio of 0.46 reflects a relatively conservative capital structure, with long-term debt of 561,300 CAD compared to total equity of 1,209,380 CAD. However, the company's net cash position is negative after subtracting total debt, signaling potential liquidity constraints.

The company's profitability metrics are negative, with a return on equity of -76.62% and a return on assets of -34.03%, indicating significant underperformance relative to its equity and asset base. These figures suggest that the company is not generating returns that justify its capital investment and is likely operating at a loss.

Rocket Doctor AI Inc does not disclose segment or geographic revenue data in the provided financials, so it is not possible to assess revenue concentration or geographic exposure. This lack of detail limits the ability to evaluate the company's diversification and potential regional risks.

The company's revenue is reported as 0 CAD, and there is no historical revenue data provided to assess growth trajectory. Analysts have assigned a mean price target of 2.10 CAD, with a mean recommendation of 2.00 (indicating a "Buy" rating), but there are no strong-buy recommendations. The absence of revenue and growth data makes it difficult to determine the company's future performance.

The company's risk assessment indicates a medium liquidity risk and a low dilution risk. The negative net cash position after subtracting total debt is a key flag, suggesting potential challenges in meeting short-term obligations. No dilution sources are explicitly identified in the provided data, and the dilution risk is assessed as low.

There are no recent events, filings, or transcripts provided in the input data to inform the company's current operational or strategic developments. This lack of recent information limits the ability to assess the company's current direction or any material changes in its business.

Key takeaways

Rocket Doctor AI Inc has a negative return on equity and return on assets, indicating poor profitability.
The company's liquidity is moderate, but its negative operating cash flow and negative net cash position after debt suggest potential liquidity constraints.
Analysts have assigned a "Buy" rating with a mean price target of 2.10 CAD, but there are no strong-buy recommendations.
The company's capital structure is relatively conservative, with a debt-to-equity ratio of 0.46.
No segment or geographic revenue data is available, limiting the ability to assess diversification and regional exposure.
The company's revenue is reported as 0 CAD, and there is no historical data to assess growth trajectory.

Bull / Bear case

Generated · model-assisted

— missing data

In focus — financials by report

Valuation FY

Market price

$0,59

Market cap

—

Enterprise valueⓘ

—

P/Eⓘ

—

Non-GAAP P/Eⓘ

—

EV / Revenueⓘ

—

EV / Op incomeⓘ

—

EV / OCFⓘ

—

P / Bⓘ

—

P / Tangible bookⓘ

—

Tangible book

$1.2M

Net cashⓘ

-$561.3k

Current ratioⓘ

1.8

Debt / equityⓘ

0.5

ROAⓘ

-34.0%

ROEⓘ

-76.6%

Cash conversionⓘ

91.0%

CapEx / revenueⓘ

—

SBC / revenueⓘ

—

Dilution ratioⓘ

0.0%

Revenue by segment

Business relationships

— missing data

Supply chain

— missing data

Peer comparison

— missing data

Market position

Stress test

— missing data

Predictor forecast

Options

— missing data

Short squeeze

— missing data

Earnings-call key lines

— missing data

Consensus distribution

sell-side coverage

Recommendation distribution1 analysts

Strong buy0

Buy1

Hold0

Sell0

Strong sell0

12-month price target$2,10 · Median $2,10

Low $2,10High $2,10

Operating income · consensus-10,5B CAD

Estimate revisions

consensus EPS · 26-week trend

— missing data

Sell-side observations

Low$2,10

Mean$2,10

Median$2,10

High$2,10

Spot$0,59

+255.9 %implied to mean12-month sell-side price targets · ▲ spot

Themes

— missing data

ESG

— missing data

Risk factors

Dilution riskLow

Liquidity riskMedium

Filing-based flags

Net cash is negative after subtracting total debt.

Benchmarks vs cohort

ROE-76,6 %Bottom quartile

D/E0,46Bottom quartile

Cash Conv0,91Above median

Corporate actions / M&A

— missing data

FX exposure

— missing data

Comparable transactions

— missing data

Derivatives & instruments

— missing data

Actions

Set alert Open in charts

Ask Handelsavisen

— missing data

Data sources

Market data
Market data cache
Issuer disclosures
Public news
Earnings transcripts
Consensus estimates
ESG data

How metrics are computed

Dilution Ratio
(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
Net Cash
cash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
Return On Equity
net_income / total_equity
Debt To Equity
(short_term_debt + long_term_debt) / total_equity
Cash Conversion Ratio
operating_cash_flow / net_income
Return On Assets
net_income / total_assets

Source documents

Rocket Doctor AI Inc Market data — financials · 2026-05-27
Rocket Doctor AI Inc Market data — analyst estimates · 2026-05-27

Ownership & reference

Insider activity

— missing data

Short positioning

— missing data

Geographic breakdown

— missing data

Listings · one canonical issuer all listings resolve to the canonical

AIDR.CDCanonical

— · USD

Intel & risk

peak dispatch · —

OSINT findings

Dilution riskLow

Liquidity riskMedium

Net cash is negative after subtracting total debt.

Evidence & claims

From filings & derived data

— missing data

The Thread

Everything we know, in order

— missing data

Sources filings · IR · transcripts · market data · tier hybrid · as of 2026-08-04 Market data · Issuer disclosures · Public news · Earnings transcripts · Consensus estimates · ESG data Premium coverage

Analyst recommendations

At a glance

What drives this business

News & coverage

Sector rotation

Developing storylines

Analysis

Opportunity

Upcoming catalysts

Pre-earnings brief

Signals & dispatch

Composite-score breakdown

Synthesis

Bull / Bear case

In focus — financials by report

Valuation FY

Revenue by segment

Market share

Business relationships

Supply chain

Peer comparison

Market position

Stress test

Predictor forecast

Options

Short squeeze

Earnings-call key lines

Consensus distribution

Estimate revisions

Sell-side observations

Themes

ESG

Risk factors

Benchmarks vs cohort

Corporate actions / M&A

FX exposure

Comparable transactions

Derivatives & instruments

Actions

Ask Handelsavisen

Ownership & reference

Insider activity

Short positioning

Geographic breakdown

Intel & risk

Evidence & claims

The Thread